Section Arrow
PHVS.NASDAQ
- Pharvaris NV
Quotes are at least 15-min delayed:2024/12/24 12:35 EST
Last
 18.96
+0.03 (+0.16%)
Day High 
19.02 
Prev. Close
18.93 
1-M High
24.52 
Volume 
11.01K 
Bid
18.77
Ask
19.27
Day Low
18.32 
Open
18.94 
1-M Low
17.82 
Market Cap 
1.03B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 18.81 
20-SMA 19.82 
50-SMA 21.14 
52-W High 33 
52-W Low 15.37 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.60/-3.09
Enterprise Value
1.03B
Balance Sheet
Book Value Per Share
5.66
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.3852-0.0179-4.44%-- 
CMNDClearmind Medicine1.61+0.39+31.97%0.16PE
CEROCERo Therapeutics Holdings0.0595+0.009+17.82%-- 
RXRXRecursion Pharmaceuticals7.195+0.205+2.93%-- 
CDTConduit Pharmaceuticals0.0592+0.0047+8.62%-- 
Quotes are at least 15-min delayed:2024/12/24 12:35 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.